Physician profile
Luke Yoon
NPI 1114007747
$5,163.74
in general payments reported to CMS, 2019-2025
24 companies · $2,686 in 2025
The $2,686 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $160 · 2021: $634 · 2022: $501 · 2023: $683 · 2024: $180 · 2025: $2,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $1,927 · Food and Beverage: $1,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $1,927.23 |
| Food and Beverage | $1,621.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $1,927.23 | 2025 | |
| Myriad Genetic Laboratories, INC. | $433.61 | 2021-2023 | Prolaris |
| Astellas Pharma US INC | $405.92 | 2019-2025 | Xtandi |
| Pfizer INC. | $404.91 | 2019-2025 | |
| Janssen Biotech, INC. | $352.85 | 2019-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $269.56 | 2022-2025 | |
| Myovant Sciences INC. | $215.39 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $188.10 | 2023-2025 | Gemtesa, Orgovyx |
| Coloplast Corp | $169.20 | 2021-2023 | Titan |
| Teleflex LLC | $160.84 | 2021-2025 | Urolift, Barrigel |
| Endo Pharmaceuticals INC. | $108.10 | 2021-2023 | Xiaflex |
| Boston Scientific Corporation | $102.95 | 2019-2024 | Ams 700 |
| Abbvie INC. | $72.32 | 2021-2023 | Lupron Depot |
| Allergan, INC. | $59.97 | 2019-2021 | |
| Urovant Sciences INC | $51.43 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $40.62 | 2024-2025 | Xiaflex |
| Urogen Pharma, INC. | $37.43 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $30.68 | 2023 | Dupixent |
| Dendreon Pharmaceuticals LLC | $27.00 | 2019 | |
| Ferring Pharmaceuticals INC. | $25.69 | 2019 | |
| Telix Pharmaceuticals | $25.04 | 2023 | Illuccix |
| Astrazeneca Pharmaceuticals LP | $22.10 | 2025 | Lynparza |
| Alk-Abello, INC | $18.13 | 2023 | Odactra, Ragwitek, Grastek |
| Accord Healthcare, INC. | $14.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Yoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.